Key Points
- CEO insider selling: Joseph Burnett sold 2,943 shares on Jan. 26 at an average price of $15.57 (~$45,823) and earlier sold 20,000 shares on Jan. 9 at $16.12, totaling 22,943 shares sold in January; after the Jan. 26 sale he holds 214,116 shares (a 1.36% reduction).
- Company fundamentals and sentiment: ClearPoint Neuro has a $409M market cap, negative earnings (missed Q), and revenue of $5.36M vs. $9.6M expected, while analysts show a mixed view (consensus "Hold" with a $9.00 price target and recent sell ratings from some firms).
ClearPoint Neuro, Inc. (NASDAQ:CLPT - Get Free Report) CEO Joseph Burnett sold 2,943 shares of ClearPoint Neuro stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $15.57, for a total value of $45,822.51. Following the completion of the sale, the chief executive officer owned 214,116 shares of the company's stock, valued at approximately $3,333,786.12. The trade was a 1.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Joseph Burnett also recently made the following trade(s):
- On Friday, January 9th, Joseph Burnett sold 20,000 shares of ClearPoint Neuro stock. The shares were sold at an average price of $16.12, for a total transaction of $322,400.00.
ClearPoint Neuro Stock Performance
ClearPoint Neuro stock opened at $14.39 on Wednesday. The company has a market cap of $409.01 million, a PE ratio of -17.13 and a beta of 0.91. The company has a current ratio of 6.37, a quick ratio of 5.56 and a debt-to-equity ratio of 1.84. ClearPoint Neuro, Inc. has a 1 year low of $9.76 and a 1 year high of $30.10. The company's 50-day moving average is $14.15 and its two-hundred day moving average is $15.25.
ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). ClearPoint Neuro had a negative return on equity of 114.28% and a negative net margin of 67.40%.The business had revenue of $5.36 million for the quarter, compared to the consensus estimate of $9.60 million. Equities analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.
Institutional Trading of ClearPoint Neuro
Several hedge funds have recently added to or reduced their stakes in CLPT. Parsons Capital Management Inc. RI lifted its holdings in ClearPoint Neuro by 0.7% during the second quarter. Parsons Capital Management Inc. RI now owns 143,486 shares of the company's stock worth $1,713,000 after acquiring an additional 950 shares in the last quarter. MGO One Seven LLC raised its position in shares of ClearPoint Neuro by 6.0% during the third quarter. MGO One Seven LLC now owns 19,026 shares of the company's stock worth $415,000 after purchasing an additional 1,077 shares during the period. Financial Management Professionals Inc. bought a new position in shares of ClearPoint Neuro during the 3rd quarter valued at about $28,000. Pekin Hardy Strauss Inc. lifted its holdings in shares of ClearPoint Neuro by 3.6% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 50,575 shares of the company's stock valued at $604,000 after purchasing an additional 1,750 shares in the last quarter. Finally, Allworth Financial LP grew its position in shares of ClearPoint Neuro by 3,076.9% in the 2nd quarter. Allworth Financial LP now owns 2,065 shares of the company's stock valued at $25,000 after purchasing an additional 2,000 shares during the period. Institutional investors and hedge funds own 30.08% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages recently commented on CLPT. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ClearPoint Neuro in a research note on Wednesday, January 21st. Wall Street Zen lowered ClearPoint Neuro from a "hold" rating to a "sell" rating in a research report on Saturday, November 15th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $9.00.
Read Our Latest Analysis on CLPT
ClearPoint Neuro Company Profile
(
Get Free Report)
ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company's flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.
The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
